Nuvectis Pharma, Inc.

US$20.91As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:NVCTHealthcare
Country USA
PE (Fwd) •••
TSR 5Y CAGR 26.77%
Div yield —
ROE (66.98%)
Biotechnology
Beta (5Y) (0.21)
PE TTM —
TSR TTM 211.62%
Mkt cap US$719.1M
ROIC (43.25%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$22
4.53%
(63.47%)
Hold 11|6|7|8|12
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.26
0.29
0.31
0.30
27.78%
31.73%
27.22%
24.21%
Revenue$M
42.42
44.90
46.85
48.46
(2.22%)
2.01%
9.12%
13.85%
Peers (US$719.1M)
Cap (US$)
PE
724.0M
—
723.1M
4.629x
Capital
TTM
5Y
10Y
Leveragex
5.125
(0.327)
(0.306)
EBIT/Intx
2.313
0.102
0.114
Own earn%
86.93
18.97
18.94
Sh yield%
41.91
47.27
48.90
Owners
Insiders/Inst%
9.03
51.04
Short interest%
3.66
SBC / revenue%
5.59
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
6
Op margin range%
5–9
$1 testx
—
Incr. ROIC%
33